NCT06388551View on ClinicalTrials.gov

A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 10, 2024

Primary Completion Date

March 30, 2025

Study Completion Date

March 30, 2025

Conditions
Hallucinations and Delusions Associated With Alzheimer's Disease PsychosisHallucinations and Delusions Associated With Parkinson Disease PsychosisNegative Symptoms of Schizophrenia
Interventions
DRUG

LY03017

single dose, administered orally

DRUG

LY03017-Placebo

single dose, administered orally

Trial Locations (1)

Unknown

Shanghai Mental Health Center, Shanghai

All Listed Sponsors
lead

Luye Pharma Group Ltd.

INDUSTRY